NATCO Pharma to acquire Dash Pharmaceuticals LLC

NATCO Pharma Limited through its affiliates is proposing to enter into an agreement to acquire Dash Pharmaceuticals LLC ("Dash") subject to satisfactory completion of due diligence, execution of definitive agreements and compliance with statutory requirements. Dash is a front-end pharmaceutical sales, marketing and distribution entity based in New Jersey, USA which is expected to have approximate net sales of USD 15 million for the year ending December 2021.

This acquisition provides NATCO with a front-end to engage with its customers directly in the USA which is the largest pharmaceutical market in the world.

The Cash consideration for the above acquisition is US$ 18 million.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 883.20 as compared to the previous close of Rs. 869.40. The total number of shares traded during the day was 19198 in over 1996 trades.

The stock hit an intraday high of Rs. 902.75 and intraday low of 873.00. The net turnover during the day was Rs. 17055958.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 Pharmaceuticals Acquisition DashPharmaceuticals USA